Skip to content

PORCINE XENOGRAFT OR MICROBIAL CELLULOSE IN THE TREATMENT OF PARTIAL THICKNESS BURNS

PORCINE XENOGRAFT OR MICROBIAL CELLULOSE IN THE TREATMENT OF PARTIAL THICKNESS BURNS - A RANDOMISED CLINICAL TRIAL

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04412759
Enrollment
26
Registered
2020-06-02
Start date
2016-06-30
Completion date
2019-11-30
Last updated
2020-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burns, Burn Scar, Burn Second Degree

Brief summary

The purpose of this study was to compare two wound dressing products for partial thickness burns in adults.

Detailed description

After being informed about the study, all patients that had given written informed consent underwent screening. If eligible study participants were randomized to be treated wih either the standard dressing of care; pigskin or a microbial cellulose. Dressing were applied within 72 hours after burn injury. Evaluation was done in an open manner due to the specific characteristics of the dressings. Study particpants were followed weekly until complete wound closure and after that evaluated at 6 and 12 months after injruy for burn scar outcome.

Interventions

OTHERmicrobial cellulose

polymer dressing synthesized in abundance with Acetobacter Xylinum

Sponsors

University Hospital, Linkoeping
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Study participants admitted within 72 hours of injury * partial-thickness burns requiring a temporary skin cover * written informed consent

Exclusion criteria

* severe coexisting cutaneous trauma * chronic or current skin disease, * severe cognitive dysfunction or psychiatric disorder * pregnant or breast feeding women were excluded.

Design outcomes

Primary

MeasureTime frameDescription
Time to complete healing of the burnEvaluated at each visit (1-3 times per week) from admission until complete healing, up to 6 monthsHealing time was calculated from the date of injury to the date when the wound bed was assessed as completely (100 %) re-epithelialized, with no need for further dressing changes other than protection against shearing according to the treating physician.

Secondary

MeasureTime frameDescription
Burn wound infectionEvaluated at each visit (1-3 times per week) from admission until complete healing, up to 6 monthsWound infections were diagnosed (by the burn surgeon) if they fulfilled at least two of the following criteria: (based on the American Burn Association definition of burn wound infection) * Clinical signs such as localised pain and swelling, spreading erythema, and heat at the affected site. * Positive bacterial culture growth of the surface wound swab. * Signs of systemic infection indicated by a rise in CRP concentration (reference range \< 10 mg/L for capillary sampling) together with increased body temperature where other sources of infection have been excluded.
Burn wound painEvaluated at each visit (1-3 times per week) from admission until complete healing, up to 6 monthsThe patients were asked to estimate the burn wound pain at rest, during activity, and during dressing changes using a numerical rating scale (NRS) where 0 indicated no pain and 10 the worst pain ever imaginable.
Duration of hospital stay (LOS)From admission until discharge, up to 6 monthsAll patients hospitalized for their burns were monitored by the study nurse and the day of discharge was noted in the CRF. Any readmission after initial discharge was also noted and included in the total length of stay.
Burn scar outcomeEvaluated at six and 12 months after injuryBurn scar outcome was evaluated using the Patient Observer Scar Assessment Scale (POSAS). The scale includes two separate subscales, The Observer Sscale, used by an experienced burn occupational therapist and the Patient Sscale, used by the study participants.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026